Toronto, Ontario — November 5, 2025 — Leads & Copy — Arch Biopartners Inc. (TSX Venture: ARCH, OTCQB: ACHFF) announced that the Fraser Health Research Ethics Board has approved the Royal Columbian Hospital’s participation in its Phase II trial evaluating LSALT peptide for cardiac surgery-associated acute kidney injury. The clinical team will complete operational approvals and training before patient enrollment, making RCH the eighth site globally and fourth in Canada. The University Health Network’s Toronto General Hospital and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial. Unity Health’s St. Michael’s Hospital is awaiting final authorization from Clinical Trials Ontario to proceed to site activation and patient enrollment.
The TSX Venture Exchange has granted final approval for Arch’s acquisition of Lipdro Therapeutics Inc. for 250,000 common shares and a royalty on future net sales of specific chronic kidney disease drug candidates targeting IL-32. The company’s Board of Directors has also granted 750,000 stock options to directors and officers at $1.70 per share for ten years, effective November 4, 2025.
Arch Biopartners Inc. is a therapeutic biotech company focused on developing novel drugs for acute and chronic kidney diseases. Its pipeline includes LSALT peptide, Cilastatin, and CKD Therapeutics.
Aaron Benson
Director of Communications
Arch Biopartners Inc.
647-428-7031
Send a message or subscribe for email alerts at: www.archbiopartners.com/contact-us
Source: Arch Biopartners
